![Mark J. Bamberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark J. Bamberger
Keine laufenden Positionen mehr
Profil
Mark J.
Bamberger worked as the Director of Cardiovascular Disease Research at Pfizer Inc. from 2004 to 2008.
He also served as the Chief Scientific Officer at Stealth BioTherapeutics Corp.
from 2014 to 2020.
Bamberger received his undergraduate degree from St. Joseph's University in 1974 and his doctorate from Drexel University College of Medicine.
Ehemalige bekannte Positionen von Mark J. Bamberger
| Unternehmen | Position | Ende |
|---|---|---|
| STEALTH BIOTHERAPEUTICS CORP | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2020 |
| PFIZER INC. | Corporate Officer/Principal | 01.01.2008 |
Ausbildung von Mark J. Bamberger
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
92
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
St. Joseph's University
 St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Drexel University College of Medicine
 Drexel University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops investigational drugs for the treatment of diseases involving mitochondrial dysfunction | Health Technology |
